ストックスクリーナーアプリを入手
50.11
5.94%
2.81
アフターアワーズ：
50.11
前日終値:
$47.30
開ける：
$47.74
24時間の取引高:
1.32M
Relative Volume:
0.94
時価総額：
$7.24B
収益：
-
当期純損益:
$-766.63M
株価収益率:
-8.7834
EPS:
-5.7051
ネットキャッシュフロー:
$-712.55M
1週間 パフォーマンス:
+2.73%
1か月 パフォーマンス:
-15.77%
6か月 パフォーマンス:
+0.93%
1年 パフォーマンス:
+54.00%
1日の値動き範囲:
$47.10
$50.25
1週間の範囲:
$46.39
$50.25
52週間の値動き範囲:
$29.08
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
50.11 | 6.83B | 0 | -766.63M | -712.55M | -5.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 繰り返されました | Needham | Buy |
| 2025-09-12 | 開始されました | Goldman | Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Top 3 Health Care Stocks You'll Regret Missing In MayVaxcyte (NASDAQ:PCVX), Universal Health Services - Benzinga
Behavioral Patterns of PCVX and Institutional Flows - Stock Traders Daily
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking a 130% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte stock (US92242T1016): clinical-stage vaccine developer draws attention after recent capital - AD HOC NEWS
Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook - Quiver Quantitative
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending - simplywall.st
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Over 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu - AD HOC NEWS
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused - AD HOC NEWS
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership - Stock Titan
Jones Hill Capital LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
(PCVX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
DIADEMA PARTNERS LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
TradingKey - TradingKey
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 105% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Nan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116 - Moomoo
PCVX Technical Analysis | Trend, Signals & Chart Patterns | VAXCYTE INC (NASDAQ:PCVX) - ChartMill
Vaxcyte Slides After Q1 Loss Widens as Spending Ramps Ahead of Key Phase 3 Readouts - Moomoo
Vaxcyte slides after Q1 loss widens as spending ramps ahead of key Phase 3 readouts - Quiver Quantitative
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating - Moomoo
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Higher Vaxcyte (NASDAQ: PCVX) Q1 loss as late-stage trials expand - Stock Titan
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vaxcyte | 8-K: Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Vaxcyte (NASDAQ: PCVX) advances Phase 3 VAX-31 program and holds $2.7B cash - Stock Titan
FMR LLC discloses 11.4% stake in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Vaxcyte (NASDAQ:PCVX) Stock Price Down 6.8%What's Next? - MarketBeat
Vaxcyte, Inc. (PCVX) Investor Outlook: Analyzing a 91% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Jennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte Executive Compensation, Directors, and Corporate Governance Overview 2025 - Minichart
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market - Seeking Alpha
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares By Investing.com - Investing.com Canada
Vaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in Stock - MarketBeat
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares - Investing.com
Vaxcyte (PCVX) COO Jim Wassil sells 2,250 shares in Rule 10b5-1 trade - Stock Titan
PCVX (PCVX) insider James Wassil files planned sales totaling $566,913.91 - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard (PCVX) holds 7.25M Vaxcyte shares, reports 5.03% stake - Stock Titan
Pictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring the 83% Potential Upside in Vaccine Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Vaxcyte launches proposed $500M public offering of stock, warrants - MSN
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):